Key result
Ex vivo platelet aggregation testing for acetylsalicylic acid dosing showed 40% of patients required /day, 50% required /day, and 10% required 300-/day for complete inhibition.
Why the study?
Does individual dosing of acetylsalicylic acid guided by platelet aggregation testing ensure complete platelet inhibition in patients with cardiovascular diseases?
Observational (n=108)
Does individual dosing of acetylsalicylic acid guided by platelet aggregation testing ensure complete platelet inhibition in patients with cardiovascular diseases?
Individualized dosing of acetylsalicylic acid guided by platelet aggregation testing reveals that 10% of cardiovascular patients are nonresponders to standard 100 mg/day doses and require higher doses for effective platelet inhibition.
Answers are grounded in this paper and cite their sources.
May support platelet testing to guide aspirin dosing in cardiovascular disease; leaves open whether this improves outcomes.
Acetylsalicylic acid is widely used in the primary and secondary prevention of cardiovascular diseases. In the current study, we used platelet aggregation ex vivo in platelet-rich plasma induced with arachidonic acid as a routine method for the determination of the individual dose of acetylsalicylic acid necessary to inhibit platelet aggregation in 108 patients with cardiovascular diseases. In 40% of all patients studied, a dose of 30 mg/day was sufficient to block the arachidonic acid-induced platelet aggregation nearly completely. In 50% of all patients, a dose of 100 mg/day was necessary. In 10% of all patients, the dose had to be further increased to 300 mg/day or even to 500 mg/day to inhibit platelet aggregation nearly completely. These results demonstrate that platelet aggregation can be used as a simple routine laboratory method to control acetylsalicylic acid treatment in patients with cardiovascular diseases and to determine individual doses of acetylsalicylic acid for a nearly complete inhibition of platelet aggregation. With a standard dose of 100 mg/day, 10% of the patients were nonresponders.
No takes yet. Share an insight, caveat, or question.
Syrbe et al. (2001) conducted an observational in Cardiovascular diseases (n=108). Ex vivo platelet aggregation testing was evaluated on Dose of acetylsalicylic acid necessary to inhibit platelet aggregation. Ex vivo platelet aggregation testing for acetylsalicylic acid dosing showed 40% of patients required /day, 50% required /day, and 10% required 300-/day for complete inhibition.
Synapse has enriched 10 related papers. Consider them for comparative context: